140 related articles for article (PubMed ID: 19641474)
1. Biological correlates of the maximum 18-fluoro-2-deoxy-glucose uptake on positron emission tomography in non-small cell lung carcinoma after induction chemotherapy.
Dooms C; Verbeken E; Stroobants S; Vansteenkiste J
J Thorac Oncol; 2009 Oct; 4(10):1221-5. PubMed ID: 19641474
[TBL] [Abstract][Full Text] [Related]
2. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
3. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index.
Vesselle H; Salskov A; Turcotte E; Wiens L; Schmidt R; Jordan CD; Vallières E; Wood DE
J Thorac Oncol; 2008 Sep; 3(9):971-8. PubMed ID: 18758298
[TBL] [Abstract][Full Text] [Related]
4. Association between 18F-fluoro-2-deoxy-D-glucose uptake values and tumor vitality: prognostic value of positron emission tomography in early-stage non-small cell lung cancer.
Dooms C; van Baardwijk A; Verbeken E; van Suylen RJ; Stroobants S; De Ruysscher D; Vansteenkiste J
J Thorac Oncol; 2009 Jul; 4(7):822-8. PubMed ID: 19487964
[TBL] [Abstract][Full Text] [Related]
5. Prognostic stratification of stage IIIA-N2 non-small-cell lung cancer after induction chemotherapy: a model based on the combination of morphometric-pathologic response in mediastinal nodes and primary tumor response on serial 18-fluoro-2-deoxy-glucose positron emission tomography.
Dooms C; Verbeken E; Stroobants S; Nackaerts K; De Leyn P; Vansteenkiste J
J Clin Oncol; 2008 Mar; 26(7):1128-34. PubMed ID: 18309948
[TBL] [Abstract][Full Text] [Related]
6. Tumour metabolic activity measured by fluorodeoxyglucose positron emission tomography for radiotherapy planning as a prognostic factor for locally advanced non-small cell lung cancer.
Masarykova A; Scepanovic D; Povinec P; Bires P; Lederleitner D; Pobijakova M
Bratisl Lek Listy; 2018; 119(3):133-138. PubMed ID: 29536740
[TBL] [Abstract][Full Text] [Related]
7. Value of combined interpretation of computed tomography response and positron emission tomography response for prediction of prognosis after neoadjuvant chemotherapy in non-small cell lung cancer.
Lee HY; Lee HJ; Kim YT; Kang CH; Jang BG; Chung DH; Goo JM; Park CM; Lee CH; Kang KW
J Thorac Oncol; 2010 Apr; 5(4):497-503. PubMed ID: 20195167
[TBL] [Abstract][Full Text] [Related]
8. Correlation of the standardized uptake value in FDG-PET with the expression level of cell-cycle-related molecular biomarkers in resected non-small cell lung cancers.
Nakamura H; Hirata T; Kitamura H; Nishikawa J
Ann Thorac Cardiovasc Surg; 2009 Oct; 15(5):304-10. PubMed ID: 19901884
[TBL] [Abstract][Full Text] [Related]
9. The value of [18F]fluoro-2-deoxy-D-glucose positron emission tomography in the selection of patients with stage IIIA-N2 non-small cell lung cancer for combined modality treatment.
Hoekstra CJ; Stroobants SG; Hoekstra OS; Vansteenkiste J; Biesma B; Schramel FJ; van Zandwijk N; van Tinteren H; Smit EF
Lung Cancer; 2003 Feb; 39(2):151-7. PubMed ID: 12581567
[TBL] [Abstract][Full Text] [Related]
10. Value of F-18-fluorodeoxyglucose positron emission tomography after induction therapy of locally advanced bronchogenic carcinoma.
Hellwig D; Graeter TP; Ukena D; Georg T; Kirsch CM; Schäfers HJ
J Thorac Cardiovasc Surg; 2004 Dec; 128(6):892-9. PubMed ID: 15573074
[TBL] [Abstract][Full Text] [Related]
11. The maximum uptake of (18)F-deoxyglucose on positron emission tomography scan correlates with survival, hypoxia inducible factor-1alpha and GLUT-1 in non-small cell lung cancer.
van Baardwijk A; Dooms C; van Suylen RJ; Verbeken E; Hochstenbag M; Dehing-Oberije C; Rupa D; Pastorekova S; Stroobants S; Buell U; Lambin P; Vansteenkiste J; De Ruysscher D
Eur J Cancer; 2007 Jun; 43(9):1392-8. PubMed ID: 17512190
[TBL] [Abstract][Full Text] [Related]
12. The association of 18F-deoxyglucose (FDG) uptake of PET with polymorphisms in the glucose transporter gene (SLC2A1) and hypoxia-related genes (HIF1A, VEGFA, APEX1) in non-small cell lung cancer. SLC2A1 polymorphisms and FDG-PET in NSCLC patients.
Kim SJ; Hwang SH; Kim IJ; Lee MK; Lee CH; Lee SY; Lee EY
J Exp Clin Cancer Res; 2010 Jun; 29(1):69. PubMed ID: 20540786
[TBL] [Abstract][Full Text] [Related]
13. Association between [18F]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1α and glucose transporter 1 in non-small cell lung cancer.
Furukawa T; Miyata Y; Kushitani K; Mimae T; Tsutani Y; Takeshima Y; Okada M
Jpn J Clin Oncol; 2015 Dec; 45(12):1154-61. PubMed ID: 26386467
[TBL] [Abstract][Full Text] [Related]
14. Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma.
Schuurbiers OC; Meijer TW; Kaanders JH; Looijen-Salamon MG; de Geus-Oei LF; van der Drift MA; van der Heijden EH; Oyen WJ; Visser EP; Span PN; Bussink J
J Thorac Oncol; 2014 Oct; 9(10):1485-93. PubMed ID: 25170642
[TBL] [Abstract][Full Text] [Related]
15. Correlation of angiogenesis with 18F-FMT and 18F-FDG uptake in non-small cell lung cancer.
Kaira K; Oriuchi N; Shimizu K; Ishikita T; Higuchi T; Imai H; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Kanai Y; Endou H; Nakajima T; Endo K; Mori M
Cancer Sci; 2009 Apr; 100(4):753-8. PubMed ID: 19141127
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of 18F-FDG PET parameters in patients with locally advanced non-small cell lung cancer treated with induction chemotherapy.
Lee HY; Choi WH; Yoo IR; Park JK; Sung SW; Kim YS; Kang JH
Asia Pac J Clin Oncol; 2020 Feb; 16(1):70-74. PubMed ID: 31782256
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer.
Hoekstra CJ; Stroobants SG; Smit EF; Vansteenkiste J; van Tinteren H; Postmus PE; Golding RP; Biesma B; Schramel FJ; van Zandwijk N; Lammertsma AA; Hoekstra OS
J Clin Oncol; 2005 Nov; 23(33):8362-70. PubMed ID: 16293866
[TBL] [Abstract][Full Text] [Related]
18. Predicting tumor hypoxia in non-small cell lung cancer by combining CT, FDG PET and dynamic contrast-enhanced CT.
Even AJG; Reymen B; La Fontaine MD; Das M; Jochems A; Mottaghy FM; Belderbos JSA; De Ruysscher D; Lambin P; van Elmpt W
Acta Oncol; 2017 Nov; 56(11):1591-1596. PubMed ID: 28840770
[TBL] [Abstract][Full Text] [Related]
19. Biologic correlates of ¹⁸F-FDG uptake on PET in pulmonary pleomorphic carcinoma.
Kaira K; Endo M; Abe M; Nakagawa K; Ohde Y; Okumura T; Takahashi T; Murakami H; Tsuya A; Nakamura Y; Naito T; Hayashi I; Kondo H; Nakajima T; Yamamoto N
Lung Cancer; 2011 Feb; 71(2):144-50. PubMed ID: 20646779
[TBL] [Abstract][Full Text] [Related]
20. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values.
Nguyen XC; Lee WW; Chung JH; Park SY; Sung SW; Kim YK; So Y; Lee DS; Chung JK; Lee MC; Kim SE
Eur J Radiol; 2007 May; 62(2):214-9. PubMed ID: 17239556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
